Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (8233)	1/7/1999 3:22:00 PM
From: aknahow	Respond to of 17367

Just a comment, I think Genentech really thinks XOMA did a great job for them. Remember the 1996 Genentech annual report had about 7 mentions of XOMA. So it was great sex and I don't doubt they would consider doing it again. But at this point they must think of things like cost , (not just current cost, but how much more would XOMA be due in profit sharing if the product gets to market after XOMA ran P III), their own ability to manage the project. Why not farmout P I and II and bring projects back in house if they reach P III, etc.etc. Believe it or not I thought the "endorsement" by Genentech was worth as much as the #2,000,000. If over the long run it results in a 5 cents higher per share price thats a bit over the 2 million. <g>